Objective: To identify molecular prognostic factors and potentially actionable mutations in ampulla of Vater cancer (AVC). Background: The largely variable outcomes of AVCs make clinical decisions difficult regarding the need of postsurgical therapy, which is based on morphological and immunohistochemical classification that do not adequately consider the varying degrees of heterogeneity present in many AVCs. No approved targeted therapies for AVC exist, but some show promising results requiring better molecular characterization to identify potential responders. Methods: We assessed 80 AVCs for the prognostic value of mutations of kirsten rat sarcoma (KRAS), neuroblastoma RAS (NRAS), B rapidly accelerated fibrosarcoma (BRAF), TP53, and 4 membrane erythroblastosis oncogene B (ERBB) receptor tyrosine kinases (EGFR-ERBB1, HER2-ERBB2, HER3-ERBB3, HER4-ERBB4) amenable to pharmacological inhibition. Moreover, we evaluated mutations in 16 key components of rat sarcoma (RAS), phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K), protein 53 (P53), transforming growth factor beta (TGF-b), and wingless/integrated (WNT) pathways, recently associated to AVC by whole-exome sequencing. Results: TP53 and KRAS were mutated in 41% and 35% of cases, respectively, and emerged as independent prognostic factors together with tumor stage and regardless of the histotype (TP53: P ¼ 0.0006; KRAS: P ¼ 0.0018; stage IIB: P ¼ 0.0117; stage III-IV: P ¼ 0.0020). ERBB, WNT and PI3K pathway genes were mutated in 37.5% of cases. Conclusions: KRAS and TP53 mutations are negative predictors of survival in AVCs, regardless of histotype. Potentially actionable mutations in ERBB, WNT, and PI3K signaling pathway genes are present in 37.5% of all cases. These might be amenable to target therapy using available drugs like Everolimus in PI3K-mutated cases or compounds under active screening against ERBB and WNT signaling.
A mpulla of Vater carcinomas (AVCs) account for up to 36% of pancreaticoduodenectomies. 1, 2 Although having a better prognosis than pancreatic ductal adenocarcinoma (PDAC), AVC remains a deadly disease, killing 60% of affected patients. [1] [2] [3] [4] This demands identification of molecular markers for prognostic stratification of resected patients and to direct therapeutic selection for patients requiring adjuvant therapy.
Genetic alterations of kirsten rat sarcoma (KRAS), TP53, CDKN2A, and SMAD4 have been reported in AVCs, thus hypothesizing a relation between AVC and PDAC. [5] [6] [7] On the other hand, the finding of adenomatous polyposis coli (APC) mutations and chromosome 5 losses occurring at early stages of AVC pathogenesis in a proportion of cases suggests a relationship with colon cancer. 8, 9 Ampulla of Vater carcinomas may arise from 1 of the 3 different epithelia forming the ampulla: duodenum, bile duct, and pancreatic duct, and can be classified into 3 distinct histological subtypes according to morphological and immunophenotypical characteristics: intestinal, pancreatobiliary, and mixed type. 2, 4, 5, [10] [11] [12] [13] [14] However, the prognostic role of these subtypes is controversial. 3, 5, 13, [15] [16] [17] [18] [19] [20] [21] [22] [23] Two recent whole-exome sequencing studies expanded our knowledge of the genetic features of AVC. 24, 25 Alteration of rat sarcoma (RAS), protein 53 (P53), phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K), and wingless/integrated (WNT) pathways was confirmed across all AVC histologic subtypes. Similarly, genes of the erythroblastosis oncogene B (ERBB) family were mutated at comparable rates in all AVC subtypes, confirming the involvement of these receptor tyrosine kinases previously reported in a small series of AVCs. 26 Of interest, the epidermal growth factor receptor (EGFR) receptor tyrosine kinase inhibitor cetuximab already showed some efficacy for the treatment of AVC when combined with chemotherapy (reviewed in 27 ). Studies analyzing the prognostic value of KRAS mutations in AVC reported conflicting results. [28] [29] [30] [31] Whereas some reports did not detect significant association between KRAS mutations and prognosis, 28 , 29 Schultz et al 30 found that KRAS mutation was a predictor of poor prognosis in a cohort of 107 AVCs, and Valsangkar et al 31 reported KRAS p.G12D mutation as potentially linked to poorer prognosis compared with other KRAS codon 12 and 13 mutations in a cohort of 75 AVCs.
In the present study, we examined a cohort of 80 AVCs to assess the prognostic value of KRAS, neuroblastoma RAS (NRAS), B From the A series of 80 surgically resected AVCs, comprising 36 freshfrozen (FF) and 44 formalin-fixed paraffin-embedded (FFPE) samples, was retrieved from the ARC-Net Biobank at the University Hospital of Verona. The selection criteria were: unequivocal establishment of origin from the anatomical structures of the ampulla of Vater; treatment of patients with curative intent by surgery alone with tumor-free margins (R0); adequate research tissue quantity; permission to use tissue in targeted sequencing; and availability of complete clinicopathological data. Follow-up information through annual direct contact with patient or physician was available for 73 cases.
Ethics
Biological material and associated clincopathological data were collected under biobank Program 1885 protocol 52438, November 23, 2010, approved by the Verona University Hospital Ethics Committee including patient informed consent. This program was amended under protocol 31149 dated July 2, 2012 to acquisition of retrospective cases from pathology archives through a waiver and data anonymization. 
Immunohistochemistry
Immunostaining to define AVC phenotype (intestinal, pancreatobiliary, or mixed) was performed as reported elsewhere 10 on FFPE samples using the following antibodies: mucin (MUC)1, MUC2, CDX2, CK7, and CK20 (Supplementary Table S2 , http:// links.lww.com/SLA/B102). Normal pancreas and duodenal mucosa were used as controls. Cytoplasmic immunoreactivity for CK7, CK20, and MUC2, cell surface staining for MUC1, and nuclear staining for CDX2 were assessed. Immunostaining was scored as positive when >25% of tumor cells were stained. 10 
DNA Extraction and Evaluation
DNA was obtained after enrichment for neoplastic cells by manual microdissection. For frozen samples, 15 consecutive 10-mm cryostatic sections were obtained, and neoplastic cellularity was checked on hematoxylin & eosin (H&E) 5-mm sections every 5 sections. For FFPE specimens, 10 to 20 consecutive 4-mm sections were used. DNA was extracted using the QiAamp DNA Mini Kit (Qiagen) for frozen samples and the QIAamp DNA FFPE Tissue Kit (Qiagen) for FFPE specimens. Purified DNA was qualified as reported previously. 
Sanger Sequencing
To validate the mutations detected by deep sequencing, TP53 (exons 5, 6, 7, 8) , KRAS (exons 2, 3), BRAF (exons 11, 15), EGFR (exon 7), ERBB2 (exon 20), ERBB3 (exon 14), and ERBB4 (exon 4), specific PCR fragments were analyzed by Sanger sequencing as previously described 34 ; DNA from matched non-neoplastic tissues was used to determine the somatic or germline nature of mutations.
Statistical Analysis
Kruskal-Wallis test was used to compare patient median age, after verifying that age distribution was non-Gaussian (Shapiro-Wilk test). Fisher exact test corrected for multiple comparisons (Benjamini-Hochberg) was used to compare the other clinicopathological variables, all of them being categorical. Log-rank test was used to compare Kaplan-Meier survival curves; for multivariate survival analysis, stepwise Cox proportional-hazards regression was used with selection of the best model using the ''backward'' algorithm; variables considered were AVC subtype, lymph node metastasis, vascular invasion, tumor grade, and presence of KRAS or TP53 mutation. For all analyses, a P value <0.05 was considered statistically significant. Kaplan-Meier graphs and univariate analyses were performed using Medcalc, version 14. 
RESULTS

Clinicopathological Data
The clinicopathological data are summarized in Table 1 . Tumor staging was according to TNM system. 35 The 80 AVCs were classified into intestinal-type (25 cases), pancreatobiliary-type (37 cases), and mixed/ambiguous-type (18 cases) according to morphological and immunophenotypical criteria.
Morphological Criteria
Intestinal-type was defined by tall columnar cells forming elongated glands with pseudostratified elongated nuclei, whereas pancreatobiliary-type was defined by cells with rounded nuclei forming rounded glands, as specified in the WHO 2010 blue book. Mixed-type tumors contained >10% of both histologic types.
Immunophenotypical Criteria
Immunophenotyping was based on routinely used markers: CK7, CK20, MUC1, MUC2, and CDX2. Immunopositivity for CK7 was found in a variable proportion of cells in most cases of both intestinal and pancreatobiliary morphological subtypes, paralleling literature data, 2,10,14 and was therefore considered uninformative. Thus, the combination of CK20, CDX2, MUC1, and MUC2 immunostainings was used to subtype AVCs as reported in Table 2 . The WHO classification presents MUC1 as a typical pancreatobiliary marker in ampullary cancers. As it is also true that MUC1 may be expressed by intestinal type cancers where it usually associates with higher aggressiveness, 36 we considered cases showing both intestinal markers and MUC1 in the mixed/ambiguous subtype.
The pancreatobiliary histotype resulted associated to younger age at diagnosis (P ¼ 0.04), higher grade (P ¼ 0.0016), vascular (P ¼ 0.0028) and perineural invasion (P ¼ 0.013), and showed a trend to lymph node metastasis (P ¼ 0.076) and higher tumor stage (P ¼ 0.056) ( Table 3) .
Prevalence of Mutations in the 24 Genes of the Next-generation Sequencing Panels
The AVC cohort was sequenced using 2 next-generation sequencing (NGS) panels including 24 genes from the following signaling pathways, chosen from the most frequently and consistently found in 2 recent exome sequencing studies 24, 25 : ERBB tyrosine kinases (EGFR, ERBB2, ERBB3, ERBB4), RAS (KRAS, NRAS, BRAF, MAP2K4); P53 (ATM, CDKN2A, TP53); WNT (APC, AXIN1, CTNNB1, FBXW7, SOX9); PI3K (GNAS, PIK3CA, PIK3R1, PTEN); and TGF-b (ACVR1B, ELF3, SMAD4, TGFBR2). The newly identified tumor-suppressor gene ELF3 was considered as belonging to the TGF-ß signaling pathway based on the phenotype of the knockout mouse. 37 All 80 samples produced adequate sequencing libraries. For the 36 FF samples, the mean read length was 112 bp and 99.5% of target bases was covered more than 100Â. For the 44 FFPE samples, the mean read length was 105 bp and 95.5% of target bases was covered more than 100Â. A minimum coverage of 20Â in all target bases was obtained for all 80 samples.
In 66/80 (82%) cases, at least 1 mutation was detected, whereas 14 samples had no mutations. The detected mutations are summarized below on a per-pathway basis (Fig. 1A 
ERBB Tyrosine Kinases
Mutations in ERBB-family genes were found in 11/80 (13.8%) cases: EGFR in 1 case (1.2%), ERBB2 in 3 cases (3.7%), ERBB3 in 6 cases (7.5%), and ERBB4 in 1 case (1.2%). EGFR carried a novel germline variant at codon 296 (p.P296T), never reported in literature. ERBB2 mutations at codons 777 (n ¼ 1) and 862 (n ¼ 1) were already reported in several cancers 26, 38 as activating mitogen-activated protein kinase (MAPK) signaling and sensitizing to anti-ERBB targeted agent lapatinib, 39 whereas the codon 776 mutation seems to be insensitive to lapatinib and its actionability with novel drugs is under investigation (http://imtech.res.in/raghava/cancerdr/submitkey_b.php?ran=1490&id=ERBB2). ERBB3 variants were at codon 104 (n ¼ 2), 128 (n ¼ 1), 284 (n ¼ 1), 558 (n ¼ 1), 901 (n ¼ 1), and 1216 (n ¼ 1); the variants at codons 104, 284, and 1216 have been reported in several cancer types, 40 whereas V901I has been described in colorectal cancer. 41 The variant P558L, reported in dbSNP database with no annotation about its germline/somatic nature, was heterozygous in the germline of our patient #1890 and showed an loss of heterozygosity (LOH) in tumor. Finally, a novel somatic ERBB4 mutation was identified in codon 170. All ERBB mutations were mutually exclusive (Fig. 1A) .
RAS Pathway
Mutations in RAS pathway genes were found in 32/80 (40%) cases: KRAS in 28/80 (35%) cases; BRAF and MAP2K4 in 2 cases (2.5%) each; and no mutations in NRAS. The 28 KRAS-activating mutations were in codons 12 (n ¼ 18), 13 (n ¼ 2), 14 (n ¼ 1), 59 (n ¼ 1), and 61 (n ¼ 6). All identified KRAS and BRAF mutations are activating/pathogenic (http://www.ncbi.nlm.nih.gov/clinvar/), whereas MAP2K4 mutations are novel. KRAS, BRAF, and MAP2K4 mutations were mutually exclusive (Fig. 1A) .
P53 Pathway
Mutations in TP53 were 34 in 33/80 (41%) cases, as 1 case harbored 2 mutations. All 34 TP53 mutations are predicted to inactivate the protein function (http://p53.iarc.fr; and http:// p53.free.fr/) [42] [43] [44] (Fig. 1B) . Two missense mutations were found in ATM, which were mutually exclusive with TP53 mutations (Fig. 1A) .
WNT Pathway
Mutations in WNT pathway genes were found in 16/80 (20%) cases. Five (6.3%) had activating CTNNB1 mutations; 4 (5%) had nonsense or frameshift mutations of APC; 4 had SOX9 mutations, 2 nonsense/frameshift, and 2 missense; 3 had FBXW7 mutations (3.7%), 2 with known inactivating aminoacid changes 45 ; 2 had AXIN1 (2.5%) alterations, 1 nonsense, and 1 novel missense (Fig. 1A) .
PI3K Pathway
Mutations in PI3K pathway genes were found in 11/80 (13.75%) cases: 6 (7.5%) harbored missense activating PIK3CA mutations (http://www.ncbi.nlm.nih.gov/clinvar/); 3 (3.7%) had PIK3R1 mutations, 1 nonsense, 1 frameshift, and 1 unknown impact missense; 2 had (2.5%) PTEN mutations and 1 had (1.2%) GNAS mutation (Fig. 1A) .
TGF-b Pathway
Mutations in TGF-b pathway genes were found in 11/80 (13.75%) cases: 6 (7.5%) harbored inactivating/pathogenic SMAD4 mutations; 4 (5%) had ACVR1B mutations; and 2 (2.5%) TGFBR2 and 3 ELF3 mutations. Mutations in ACVR1B and 1 TGFRB2 were novel, whereas 1 TGFRB2 mutation was pathogenic. The newly discovered ELF3 was mutated in only 3/80 cases (3.7%), at variance with recent reports describing alterations in 10% to 12% 24, 25 ( Fig. 1A) .
Distribution of Mutations in AVC Histotypes
The distribution of mutations among the 3 AVC histotypes is detailed in Supplementary Table S4 (http://links.lww.com/SLA/ B104). No significant association was found between AVC subtype and mutation distribution, either considering single genes or grouped by pathway. Notably, the 2 cases with BRAF mutations were intestinal subtype, whereas only 3 of the 11 ERBB-mutated cases were pancreatobiliary.
Concomitant Alterations in Different Pathways
We observed concomitant alterations in different pathways, with 40/80 samples (50%) carrying mutations in at least 2 different pathways (Supplementary Table S3 , http://links.lww.com/SLA/B103).
As shown in Fig. 1A , 9 of 11 cases harboring mutations in ERBB genes also bore genetic lesions in other pathways: 2 cases in WNT signaling, 2 cases in WNT and RAS, 1 case in WNT and P53, 2 cases PI3K, 1 case in P53, and 1 in RAS, P53, and TGF-b pathway. Five cases harbored a KRAS mutation with other concurrent alterations in WNT (3 cases), PI3K (1 case), or TGF-b (1 case). Fourteen cases harbored both RAS and TP53 mutations, 3 of them also had mutations in WNT, and another 1 in PI3K. Nine cases had a TP53 mutation concurring with another pathway alteration in WNT (3 cases), PI3K (1 case), PI3K, and TGF-b (1 case), or TGF-b (4 cases). One case had concurrent mutations in WNT and PI3K signaling. With the exception of this case, mutations in WNT and PI3K pathways among the whole cohort were mutually exclusive for all affected cases, whereas they frequently co-occurred with ERBB or RAS pathways alterations.
KRAS and TP53 Mutations Correlate With Poor Survival
KRAS and TP53 were the most frequently mutated genes, respectively occurring in 28/80 (35%) and 33/80 (41%) cases, with no apparent difference of distribution among the 3 AVC histological subtypes. Survival analysis was performed on 73 cases with available follow-up information (Supplementary Table S5 , http://links.lww.com/SLA/B105). At multivariate survival analysis, higher tumor stage (stage IIB, P ¼ 0.0117; stage III-IV, P ¼ 0.0020), KRAS (P ¼ 0.0018), and TP53 (P ¼ 0.0006) mutations were independent predictors of poor prognosis (Table 4) . Notably, Kaplan-Meier curve of the 73 patients showed that patients carrying TP53 mutation had a mean survival of 59 months compared with 151 months for wild-type TP53 (P ¼ 0.0004) (Fig. 2A) . Similarly, univariate survival analysis for KRAS showed that patients carrying KRAS mutation had a mean survival of 78 months compared with 138 months for wild-type KRAS (P ¼ 0.021) (Fig. 2B) . Multivariate analysis results are reinforced by the absence of correlation between KRAS and TP53 mutations (Fisher exact test P ¼ 0.23), and by the verification at univariate survival analysis that the effect of the 2 genes was additive, as expected from independent predictors (Fig. 2C) .
Histological subtype was not a significant prognostic predictor by univariate and multivariate analysis. Considering the trend between tumor stage and histological subtype (Supplementary Table 5 ) and the fact that tumor stage divides patients into small groups, especially for early stages, we cross-verified the predictive performance of histological subtype in a multivariate model excluding tumor stage. Even in this model, the histological subtype resulted nonsignificant as prognostic predictor. No mutations were found for the NRAS gene, which has therefore been excluded from the figure. B, Graphical representation of the 34 TP53 mutations identified with predicted amino acid change and location in the p53 protein domains. Colored circles indicate mutations category as described; mutations identified in more than 1 sample are illustrated by multiple circles.
DISCUSSION
The results of our study can be summarized as follows: TP53 and KRAS mutations were independent negative predictors of survival in AVC, regardless of the histotype; histological/immunophenotypical subtypes showed no prognostic value; potentially actionable mutations in ERBB, PI3K, and WNT pathway genes were found in 30/80 (37.5%) cases.
We analyzed 24 genes belonging to pathways reported to be involved in AVC tumorigenesis, 24, 25 including ERBB receptor tyrosine kinases, PI3K, and WNT pathways, which are amenable to pharmacological inhibition. At least 1 mutation was found in the majority of cases (66/80, 82%), with a significant proportion of cases (50%) carrying multiple driver gene alterations. TP53 was the most frequently mutated gene (33/80, 41% of cases) and resulted an independent negative predictor of survival at multivariate analysis. TP53 mutations have been consistently associated with poor prognosis in several cancer types, 44 and it has been shown that chromosome 17p loss, where TP53 resides, was associated with poor disease-specific survival in AVC. 46 KRAS, the second most mutated gene (28/80, 35% of cases), also resulted an independent prognostic predictor at multivariate analysis. The independent prognostic value of KRAS mutations is in line with 2 recent studies 30, 31 ; importantly, we explored all 3 exons (exons 2, 3, and 4) of KRAS and found a relevant number of mutations (7/80, 8.7%) in exon 3 (codons 59 and 61) that accounted for 25% of KRAS-mutated cases. Fifteen cases had concomitant TP53 and KRAS mutations. However, there was no interdependence between the 2 mutations (Fisher exact test P ¼ 0.23), and their effect on patient survival was additive.
The AVC histological subtype showed no prognostic value in our study, and available literature is conflicting on this topic. 13, 16, 17, [19] [20] [21] This is a major issue that hampers comparability of results, and underlines that morphological subtyping is subjective and prone to interobserver variability in a large number of cases. As it stands, concordance among pathologists is far from high even among experts in the field. 10 This is evident from the variable definition of the mixed histotype, where the percentage of composition differs, for example, some authors consider 20%, 24 others 25% 10 or 10%, 13 (and present paper) of both morphological patterns to define the mixed subtype. Immunohistochemistry has thus been proposed to aid subtyping, but, although most authors agree on the number and type of immunomarkers to use, there is no agreed standard for their interpretation. Our study panel included CK20, MUC1, MUC2, and CDX2, as used by most authors. As is evident in Table 2 , where we compared the immunohistochemical criteria used herein with other recent publications, 10, 13, 24 only MUC1 and CDX2 are considered consistent parameters, whereas cytokeratins and MUC2 are optional. However, even recent expert attempts to redefine immunohistochemistry criteria have been unable to classify all ampullary carcinomas, because 18% of the tumors had an ambiguous immunophenotype. 10 At this point, it is clear that cancer heterogeneity is the issue, and no parameters and cut-offs take this into account. In this scenario, molecular characterization could better direct treatment or observation choices in the absence of morphological and immunophenotypical parameters.
Although AVC is generally associated with good prognosis when resected with curative intent, there remains a substantial proportion of patients who relapse and die of the disease, and could benefit from adjuvant therapy if identified at time of surgery. Prognostic markers would help identify patients at higher risk of relapse, and identifying potentially actionable gene alterations would offer the possibility of exploring novel therapies using drugs already available or under evaluation in clinical trials.
In this study, mutations in the ERBB family of receptors were found in 11/80 (13.8%) cases, therefore identifying patients that could potentially benefit from therapies targeting those receptors. Notably, all mutations in receptor tyrosine kinases were mutually exclusive in our series, which is in line with current literature. 47, 48 ERBB mutations in 6 of 11 AVCs have been reported as activating, with 2 ERBB2 mutations (codons 777 and 862) also reported as sensitizing to anti-ERBB targeted agent lapatinib, 39 whereas a third ERBB2 mutation (codon 776) seems to be insensitive to lapatinib, and its actionability with novel drugs is under investigation (http:// imtech.res.in/raghava/cancerdr/submitkey_b.php?ran=1490&i-d=ERBB2). The remaining 5 ERBB variants in our cohort have never been described before and their functional impact still requires clarification. ERBB mutations co-occured with KRAS mutations in only 2 of the 11 mutated AVCs. This is clinically relevant because KRAS mutations confer resistance to targeted therapies hitting ERBB activation. 49 The PI3K and/or WNT pathways were altered in 26/80 (32.5%) cases, which might be amenable to target therapy using available drugs like everolimus 50 in PI3K-mutated cases or compounds under active screening against WNT signaling.
51 One limitation of our study is the underestimation of the number of WNT pathway APC gene alterations. This is due to primer design limitations, where our assay included only the 7 regions of APC exon 16 with the highest frequency of mutations. Our design has probably detected only 28% of APC mutations based on a comparison with the works of Gingras et al 24 and Yachida et al 25 that used whole-exome sequencing. This could impact the potential number of cases for WNT-targeted therapy. However, as APC mutations are early events in AVC pathogenesis, 9 it is implausible that this underestimation of APC mutated cases would have a prognostic impact.
CONCLUSIONS
Our analysis showed that mutational status of KRAS and TP53 are the most important prognostic factors for AVC patients, together with tumor stage. These findings call for the integration of mutational analysis in AVC pathology reporting, for an efficient prognostic FIGURE 2. Kaplan-Meier curves of 73 ampulla of Vater carcinoma patients grouped according to TP53 or KRAS mutational status. A, Patients carrying TP53 mutation face a worse prognosis, with a mean survival of 59 months compared with 151 months for patients with wild-type TP53 (P ¼ 0.0004). B, patients carrying KRAS mutation face a poorer prognosis, with a mean survival of 78 months compared with 138 months for patients with wild-type KRAS (P ¼ 0.021). C, The effect of KRAS and TP53 mutations is additive as expected for independent predictors, with a progressively poorer prognosis for cases with KRAS mutation, TP53 mutation, or both gene mutations (global survival differences P ¼ 0.0003; trend among categories P < 0.0001). Vertical axis indicates percentage of survival probability; horizontal axis indicates overall survival expressed in months. Log-rank statistics were used to determine levels of significance.
